Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The paper is concerned with the results of radiation and chemoradiotherapy of stage III-IV rhinopharyngeal cancer. Short- and long-term therapeutic results, the time of a recurrence-free course, the frequency of recurrences and metastasizing, expression of reactions, and complications were used as criteria. The most effective method of combined therapy of locally spread rhinopharyngeal cancer was polychemotherapy (bleomycetin, methotrexate, vinblastine, and cyclophosphamide) before irradiation with subsequent maintenance cyclophosphamide chemotherapy once in 4 weeks for 3-6 months. The 5-year survival rate for combined modality therapy of stage III-IV rhinopharyngeal cancer was within 62%, for radiotherapy used alone-50%.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!